← Eichor
Condition: Astrocytoma Idh Mutant Grade 2 Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Astrocytoma Idh Mutant Grade 2

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Vorasidenib Maintenance for IDH Mutant Astrocytoma
Phase 3 · 33 location(s) · European Organisation for Research and Treatment of Cancer - · NCT06809322A Study of 177Lu-PSMA-617 in People With Gliomas
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07223034PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas
NA · 1 location(s) · Oslo University Hospital · NCT05190172Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astr
Phase 1 · 43 location(s) · National Cancer Institute (NCI) · NCT06860594SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Phase 3 · 57 location(s) · Nuvation Bio Inc. · NCT05303519A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma
Phase 1/Phase 2 · 16 location(s) · Debiopharm International SA · NCT05765812
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.